Loading…
Maker of the Omnipod tubeless insulin pump system for people with diabetes.
Maker of the Omnipod tubeless insulin pump system for people with diabetes.
Earns mostly from the disposable pods that wear on the skin and are replaced every few days, so each patient becomes a recurring revenue stream, much like a subscription. Selling through pharmacies, where patients collect pods like any medicine, has widened its reach beyond the clinics that prescribed traditional pumps. Most sales are in the US.
Moat: narrow (IP / patents, switching costs, brand). Differentiated tubeless pump design and growing automated-insulin-delivery ecosystem create patient stickiness.
Headquarters: Acton, Massachusetts, USA · Founded: 2000 · Employees: 5,400
Size Insulet (PODD) is a United States Health Care company (Medical Specialties) with a market value of $10.2B, the 767th largest of 3,117 United States companies the cockpit tracks. Shares closed at $146.51 on 6 Nov 2026.
Performance Over six months the shares fell 5.0%, against +35.0% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 26.5% over the last twelve months (peer median +5.0%); the operating margin is 18.4% (peer median 13.6%).
Valuation It trades at 19.5× forward earnings against a peer median of 20.4× (9th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 14.0 points above its cost of capital (9.7% WACC).
Short interest Short interest is 8.1% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.19B | $2.71B | $2.07B | $1.70B | $1.31B |
| Revenue growth | — | +31% | +22% | +30% | — |
| Gross profit | $2.32B | $1.95B | $1.46B | $1.17B | $885M |
| EBITDA | $712M | $587M | $408M | $293M | $101M |
| Net income | $429M | $247M | $418M | $206M | $4.60M |
| Free cash flow | n/a | $378M | $305M | $69.8M | -$3.90M |
| Capital expenditure | n/a | $219M | $134M | $109M | $157M |
| Total debt | $962M | $1.00B | $1.42B | $1.45B | $1.43B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Insulet PODD | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% |
| MiniMed MMED | $4.70B | +44% | +14% | 14% | 25.5× | n/a |
| Tandem Diabetes Care TNDM | $1.18B | +9% | +4% | -4% | n/a | n/a |
| Dexcom DXCM | $29.6B | +31% | +13% | 24% | 27.0× | 18.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PODD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.9% | +10.1% | 10th lowest of 21 |
| 6-month return | -5.0% | +35.0% | 2nd lowest of 21 |
| Distance from 52-week high | -58.7% | -11.6% | lowest of 21 |
| Revenue growth (TTM) | +26.5% | +5.0% | 3rd highest of 21 |
| Operating margin | 18.4% | 13.6% | 6th highest of 21 |
| Forward P/E | 19.5× | 20.4× | 9th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 10.3% | 9.4% | 10th most demanding of 20 |
| Growth delivered (Del g) | +24.5% | +9.8% | 3rd highest of 20 |
| Hurdle (Req g minus delivered) | -14.2 pp | +1.5 pp | 2nd least demanding of 20 |
| ROIC minus cost of capital | +14.0 pp | +2.5 pp | 2nd highest of 21 |
| EV / EBITDA | 14.8× | 12.2× | 7th most expensive of 18 |
| Net debt / EBITDA | 0.5× | 1.2× | 7th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Insulet PODD | United States | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% | +24.5% |
| Bio-Rad Laboratories BIO | United States | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% | +0.3% |
| Qiagen QGEN | United States | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% | +2.2% |
| Avantor AVTR | United States | $10.5B | +86% | +1% | 8% | 17.7× | 16.1% | +0.5% |
| Globus Medical GMED | United States | $9.54B | -9% | +20% | 22% | 14.1× | 5.5% | +30.1% |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
| Demant A/S DEMANT.CO | Denmark | $11.6B | +62% | +10% | 18% | 25.7× | 6.8% | +9.8% |
| Align Technology ALGN | United States | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% | +10.3% |
| Cooper Companies (The) COO | United States | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% | +11.0% |
| Olympus 7733.T | Japan | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% | +6.7% |
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% | +5.5% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |